Celldex Therapeutics (CLDX) Consolidated Net Income (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Consolidated Net Income of -$85.9 million for Q1 2026, down 37.12% year-over-year from -$136.6 million in Q1 2025, and up 21.63% quarter-over-quarter from -$109.6 million in Q4 2025.
Celldex Therapeutics (CLDX) Consolidated Net Income (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Consolidated Net Income history runs 17 years deep, the most recent figure standing at -$85.9 million for Q1 2026.
- In Q1 2026, Consolidated Net Income fell 37.12% year-over-year to -$85.9 million; the TTM figure through Mar 2026 stood at -$326.8 million (up 34.59% YoY), while the FY2025 annual figure was -$661.6 million, down 38.51% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$85.9 million, up from -$109.6 million in the prior quarter.
- The five-year high for Consolidated Net Income was -$23.0 million in Q1 2022, with the low at -$390.7 million in Q4 2023.
- The 5-year median for Consolidated Net Income is -$47.7 million (2024), against an average of -$87.0 million.
- The sharpest annual moves came in 2023 and 2025: Consolidated Net Income slumped 1375.03% in 2023, then jumped 67.81% in 2025.
- Celldex Therapeutics' Consolidated Net Income stood at -$26.5 million in 2022, then plunged by 1375.03% to -$390.7 million in 2023, then increased by 12.83% to -$340.5 million in 2024, then surged by 67.81% to -$109.6 million in 2025, then grew by 21.63% to -$85.9 million in 2026.
- Business Quant data shows CLDX's Consolidated Net Income at -$85.9 million in Q1 2026, -$109.6 million in Q4 2025, and -$67.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | -74.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -74.89 Mn |
| Mar 31, 2026 | -85.90 Mn |
| Dec 31, 2025 | -109.62 Mn |
| Sep 30, 2025 | -67.05 Mn |
| Jun 30, 2025 | -64.20 Mn |
| Mar 31, 2025 | -62.65 Mn |
| Dec 31, 2024 | -340.55 Mn |
| Sep 30, 2024 | -48.63 Mn |
| Jun 30, 2024 | -47.73 Mn |
| Mar 31, 2024 | -42.24 Mn |
| Dec 31, 2023 | -390.69 Mn |
| Sep 30, 2023 | -41.64 Mn |
| Jun 30, 2023 | -33.78 Mn |
| Mar 31, 2023 | -32.14 Mn |
| Dec 31, 2022 | -26.49 Mn |
| Sep 30, 2022 | -26.78 Mn |
| Jun 30, 2022 | -36.00 Mn |
| Mar 31, 2022 | -23.05 Mn |
| Dec 31, 2021 | -20.15 Mn |
| Sep 30, 2021 | -20.45 Mn |